On the business side of things, Aurora Cannabis has been making nothing but good decisions. They acquired two of the best producers they could have, at the best possible time.

However, it is important to note that these acquisitions have been structured as mostly stock-deals, meaning that the shareholders of CanniMed and MedReleaf are holding a lot of Aurora Stock.

In fact, MedReleaf shareholders received 3.575 Aurora shares for each MedReleaf share they owned, giving the combined entity more than 900 million shares outstanding.

Aurora is now projected to have a market cap of over $7.5 billion CAD, behind Canopy Growth ($13.5 billion CAD) and Tilray ($11.5 billion CAD).

It is my assumption that they will play a much larger role in the global cannabis trade than their competitors, as the number of overseas deals Aurora made trumps their competitors by far.

As for their stock, it is very likely that Aurora will take much longer to rise to the numbers at which Canopy and Tilray are trading right now, but it is definitely going to happen once these overseas deals start making a difference.

Please don’t make any investments based solely on Greencamp News company and stock updates. See more